Results 111 to 120 of about 456 (124)
Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants. [PDF]
Antimicrob Agents ChemotherHodges MR +5 more
europepmc +1 more source
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants. [PDF]
Antimicrob Agents ChemotherHodges MR +6 more
europepmc +1 more source
Antimicrobial Agents and Chemotherapy, 2022 We evaluated the in vitro activity of manogepix and comparator agents against 1,435 contemporary fungal isolates collected worldwide from 73 medical centers in North America, Europe, the Asia-Pacific region, and Latin America during 2020.
Michael D Huband, Mariana Castanheira
exaly +3 more sources
Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis [PDF]
Antimicrobial Agents and Chemotherapy, 2020 There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of ...
Teclegiorgis Gebremariam +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
ABSTRACT Fosmanogepix is a new antifungal agent currently undergoing phase 3 clinical trials. Its active moiety, manogepix, inhibits Gwt1 which is an enzyme essential for the assembly and attachment of glycosylphosphatidylinositol anchors to cell wall proteins.
Sean Brazil +4 more
openaire +1 more source
Sean Brazil +4 more
openaire +1 more source